Loading...
•
Dec 31, 2021
DBV Technologies Q4 2021 Earnings Report
DBV Technologies reported full year 2021 financial results, highlighting cash runway extended into the first quarter 2023 and mVP pivotal protocol completion.
Key Takeaways
DBV Technologies reported full year 2021 financial results. The company's cash and cash equivalents were $77.3 million. Net loss was $(97.8) million under U.S. GAAP and $(98.1) million under IFRS.
Cash and cash equivalents were $77.3 million as of December 31, 2021.
Net loss was $(97.8) million under U.S. GAAP and $(98.1) million under IFRS for the year ended December 31, 2021.
Operating income was $5.7 million for the year ended December 31, 2021.
The protocol for the new Phase 3 pivotal study of the modified Viaskin Peanut (“mVP”) patch was completed at the end of February 2022 and has been prepared for FDA submission.
DBV Technologies
DBV Technologies
Forward Guidance
DBV expects that its current cash and cash equivalents will support its operations into the first quarter of 2023.
Positive Outlook
- Cash runway extended into the first quarter 2023
- mVP Pivotal Protocol Complete and Ready for Submission to FDA
- DBV Continues to Engage in Productive Exchanges with FDA
- Reduction in net cash used in operating activities
- DBV has continued to practice financial diligence and implemented further cost containment strategies.
Challenges Ahead
- Uncertainties associated generally with research and development
- Uncertainties associated with clinical trials and related regulatory reviews and approvals
- Impact of the COVID-19 pandemic
- Ability to successfully execute on its budget discipline measures
- Product candidates have not been authorized for sale in any country.